Update on the treatment of endometriosis

Sung Hoon Kim, Kim SH, Hee Dong Chae, Chae HD, Kim CH, Chung‐Hoon Kim, Chung-Hoon Kim, Byung Moon Kang, Kang BM
Clinical and experimental reproductive medicine · 2013 · vol. 40(2) , pp. 55 · doi:10.5653/cerm.2013.40.2.55 · PMID:23875160 · PMC3714429 · W2154191550
article OA: gold CC0 ⤵ 17 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review summarizes current findings on endometriosis treatment, covering surgical outcomes for pain and infertility, and the efficacy of newer drugs like aromatase inhibitors, anti-tumor necrosis factor-alpha, and dienogest.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This review summarizes up-to-date evidence on treatment of endometriosis, focusing on outcomes of laparoscopic surgery for pelvic pain and infertility, and efficacy of newer medical therapies such as aromatase inhibitors, anti–tumor necrosis factor-α agents, and dienogest, largely using recent Cochrane reviews and clinical reports. For pelvic pain, the review reports that non-comparative surgery studies usually show symptom improvement but also substantial pain recurrence or re-operation rates (reported 24%–54%), with higher repetitive surgery risk in women under 30 years and in those with pelvic pain. Controlled and meta-analytic data cited suggest laparoscopic surgery can have an advantage over diagnostic laparoscopy only for pain at 6 and 12 months, and a Cochrane review on ovarian endometrioma indicates excisional surgery is associated with reduced recurrence for several pain outcomes compared with ablative surgery, while evidence about fertility after ovarian stimulation and IUI is insufficient. This paper is centrally about endometriosis — it reviews and synthesizes current evidence on surgical and medical treatment options and outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is defined as the presence of functional endometrial tissue outside the uterus, causing diverse progressive symptoms such as infertility, pelvic pain, and dysmenorrhea. Although endometriosis has been described since the 1800s, the mechanisms responsible for its pathogenesis and progression remain poorly understood. It is well established that endometriosis grows and regresses in an estrogen-dependent fashion and the disease can be effectively cured by definitive surgery. However, prolonged medical therapy may be needed in most of the cases since conservative surgery is usually performed especially in young women. This treatment modality is often associated with only partial relief and/or recurrence of the disease. In the present review, up-to-date findings on the treatment of endometriosis will be briefly summarized. The outcomes of surgery in patients with endometriosis will be reviewed in terms of pelvic pain relief as well as infertility treatment largely based on recent Cochrane reviews and clinical reports. The efficacy of newer drugs including aromatase inhibitor, anti-tumor necrosis factor-alpha, and dienogest will be also reviewed based on recent clinical studies.
Full text 12,133 characters · extracted from pmc-nxml · 4 sections · click to expand

The

Based on the findings of increased expression of aromatase P450 in the endometriotic tissue, some investigators used AIs to treat pain symptoms in patients with endometriosis. A recent systemic review assessed the efficacy of AIs on treatment of pain caused by endometriosis [ 19 ]. The review was composed of the results of 10 publications including a total of 251 women. All of the observational studies showed that AIs combined with either progestogens or oral contraceptive pill reduce the severity of pain symptoms and improve quality of life. One randomized clinical trial demonstrated that combining letrozole with norethisterone acetate results in a lower incidence of adverse effects and lower discontinuation rate than combination of letrozole and triptorelin. Two randomized clinical trials demonstrated that postoperative AI treatment combined with GnRH analogue for 6 months reduces the risk of endometriosis recurrence when compared with GnRH analogue alone. Based on these findings, they concluded that AIs effectively reduce the severity of endometriosis-related pain symptoms. However, other researcher proposed that AIs need to be investigated further in well-designed studies to confirm the hypothetical impact on endometriotic lesions, since there have been no strong evidences favoring the efficacy or benefit of AIs compared to other hormonal drugs in currently available clinical trials [ 20 ]. Since mounting evidence showed that altered immune function plays a crucial role in the pathogenesis and pathophysiology of endometriosis, several investigators suggested that modulating the inflammation could be an alternative approach for treatment of endometriosis. A Cochrane review evaluated the effectiveness and safety of anti-TNF-α drugs in the management of pelvic pain associated with endometriosis [ 21 ]. Only one trial involving 21 participants was included in this review. Results showed no evidence of improvement of pain score or reduced use of pain killers after treating by infliximab, one of the known anti-TNF-α drugs. Although there was no evidence of an increase in adverse events in the infliximab group compared with placebo, clinical benefits of infliximab was not found with regard to endometriotic lesions, dysmenorrhea, dyspareunia or pelvic tenderness. Dienogest (Visanne, Bayer HealthCare, Berlin, Germany) is a synthetic oral progestin possessing strong progestational and moderate antigonadotrophic effects, but no androgenic, glucocorticoid or mineralocorticoid activity. A dosage of 2 mg/day only moderately suppresses estradiol levels, and has high oral bioavailability and a half-life suitable for once-daily administration. A Randomized clinical trial showed that oral dienogest is more effective than placebo in reducing pelvic pain in patients with confirmed endometriosis [ 22 ]. Clinical trials comparing oral dienogest for 16 or 24 weeks with GnRH analogues in patients with endometriosis-dienogest had similar effect on reducing pelvic pain, improvement of combined symptoms/signs scores and revised American Fertility Society staging and scores compared with GnRH analogues [ 23 ]. According to another randomized clinical trial, women in the dienogest group had less hypoestrogenic side effects and little changes in bone markers and bone mineral density, thus offer advantages in safety and tolerability [ 24 ]. However, dienogest was associated with a higher incidence of abnormal menstrual bleeding patterns, although this was generally well tolerated by patients.

Outcomes

A recent Cochrane review compared the reproductive outcomes between laparoscopic surgical interventions and diagnostic laparoscopy in patients with minimal-to-mild endometriosis [ 16 ]. Two studies were eligible for inclusion within the review and both studies compared laparoscopic surgical treatment of minimal-to-mild endometriosis with diagnostic laparoscopy only. Combining live birth rate and ongoing pregnancy after 20 weeks, the meta-analysis demonstrated an advantage of laparoscopic surgery compared to diagnostic laparoscopy only (OR, 1.64; 95% CI, 1.05 to 2.57). The meta-analysis also showed an advantage of laparoscopic surgery regarding clinical pregnancy rate (OR, 1.66; 95% CI, 1.09 to 2.51) but not demonstrating an effect of laparoscopic surgery on fetal loss. A recent Cochrane review compared fertility outcomes between excisional and ablative surgery in women with ovarian endometrioma [ 15 ]. In that review, excision of the cyst wall was associated with a higher spontaneous pregnancy rate (OR, 5.21; 95% CI, 2.04 to 13.29) compared to women who underwent laparoscopic ablation. However, there was insufficient evidence supporting excisional surgery over ablative surgery in terms of pregnancy chance after ovarian stimulation and intra-uterine insemination. A recent Cochrane review assessed the effectiveness of surgery for improving reproductive outcomes among women with endometrioma prior to undergoing ART cycles [ 17 ]. Randomized controlled trials of surgical or expectant management for endometrioma prior to ART were analyzed. Four trials with 312 participants were included. Comparing the clinical pregnancy rate between the surgery (aspiration or cystectomy) and the expectant management groups, there was no difference between the two groups. Although cystectomy was associated with a decreased ovarian response to ovarian stimulation, there was no difference in the number of mature oocytes retrieved. A guideline suggested that laparoscopic ovarian cystectomy is recommended if an ovarian endometrioma ≥4 cm in diameter is present to confirm the diagnosis histologically, reduce the risk of infection and improve access to follicles and possibly improve ovarian response [ 18 ]. It is also recommended that woman should be counseled regarding the risks of reduced ovarian function after surgery and the possibility of oophorectomy thus the decision should be reconsidered if she underwent previous ovarian surgery.

Conclusions

Based on the recent Cochrane reviews and clinical reports, treatment of endometriosis can be summarized as follows: 1) laparoscopic surgery is effective in reducing pain symptoms compared to diagnostic laparoscopy alone; 2) laparoscopic surgery is also effective in improving pregnancy rate compared to diagnostic laparoscopy alone in women with minimal-to-mild endometriosis; 3) regarding management of endometrioma prior to ART, ESHRE guideline suggested that laparoscopic ovarian cystectomy is recommended if an ovarian endometrioma is 4 cm or more in diameter, although randomized controlled trials failed to prove any advantage of ovarian cystectomy in improving pregnancy rate; 4) AIs and dienogest might be effective newer drugs for medical treatment of endometriosis, but long-term follow-up studies are necessary to estimate the cost-effectiveness of those treatments.

Introduction

Endometriosis is defined as the presence of functional endometrial tissue outside the uterus, causing diverse symptoms including infertility, chronic pelvic pain, and cyclic menstrual pain. The prevalence of endometriosis has been reported ranging from 2% to 18% among women who seek tubal ligations and from 5% to 50% of infertile women [ 1 ]. When 10% prevalence rate assumed among reproductive aged women, the annual costs attributed by the disease may be calculated as 22 billion US dollars, suggesting an enormous negative impact on national health systems [ 2 ]. Although endometriosis has been described since the 1800s, the mechanisms responsible for its pathogenesis and progression remain poorly understood. It is well established that endometriosis grows and regresses in an estrogen-dependent fashion and the disease can be effectively cured by definitive surgery. However, prolonged medical therapy may be needed in most of the cases since conservative surgery is usually performed especially in young women. This treatment modality is often associated with only partial relief and/or recurrence of the disease. In the present review, up-to-date findings on the treatment of endometriosis will be briefly summarized largely based on recent Cochrane reviews and clinical reports. Specifically, the outcomes of surgery in patients with endometriosis will be reviewed in terms of pelvic pain relief as well as infertility treatment. The efficacy of newer drugs, such as aromatase inhibitor, anti-tumor necrosis factor-alpha and dienogest, will be also reviewed based on recent clinical studies.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrheainfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (17)

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:53.335890+00:00
License: CC0 · commercial use OK